The EU funded project LEGATO officially started

The European Organisation for Research and Treatment of Cancer (EORTC) and the Syreon Research Institute are delighted to announce the official start of LEGATO, a pragmatic phase III clinical trial focusing on recurrent Glioblastoma.

LEGATO is one of three research projects coordinated by EORTC, alongside DE-ESCALATE and STREXIT- 2, which have recently received funding from the Horizon Europe Programme. The study will have a duration of five years.

About recurrent Glioblastoma

Glioblastoma is by far the most common and aggressive malignant primary brain tumour in the adult population. The average survival, following standard-of-care treatment such as surgery, radiotherapy and chemotherapy, does not exceed 15 months. Most glioblastoma patients relapse and the treatment options for recurrent Glioblastomas are limited. Currently, no standard of care exists for patients with glioblastomas at first progression. Treatment options include repeated surgery (if feasible), systemic therapy (Bevacizumab, Lomustine, Temozolomide re-challenge), reirradiation and best supportive care.


LEGATO is a comparative randomised, open-label, multicentre, phase III trial (1:1) (Lomustine alone vs. Lomustine plus reirradiation) for patients with recurrent Glioblastoma. Lomustine was selected as a chemotherapeutic agent since it is, nowadays, the standard treatment for recurrent Glioblastoma.

Legato project

This is the first official trial looking into the potential benefits of chemo-irradiation compared to chemotherapy alone to improve disease control and survival in patients burdened by this aggressive cancer.

The project funding started officially in June 2023 and the team is currently preparing documents for regulatory submission. Patient recruitment for LEGATO will start between the first and second quarter of 2024.

The LEGATO study aims not only to assess the efficacy of chemo-irradiation as a treatment for recurrent glioblastoma but also its cost-effectiveness through health economics analysis performed by Syreon Research Institute, which will assess the economic impact of the treatment at sites.
The LEGATO study will run in 11 countries in Europe, including Austria, the Czech Republic, Denmark, France, Germany, Italy, the Netherlands, Norway, Switzerland, Spain, and Belgium. The study aims to recruit 411 patients from 43 sites.

The LEGATO study may lead to improved patient survival and quality of life but also improve health system sustainability. The study is managed by a multidisciplinary and multistakeholder consortium involving clinical oncologists, nuclear medicine experts, statisticians, health economists and patient representatives. It may provide new insights in the treatment of this cancer and deeply change, worldwide, clinical practice for recurrent Glioblastoma.

Read more about the EORTC projects funded by the EU here and visit the official project’s website: 

Back to news list

Related News

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma